Prenetics Global Limited PRE
17.25 USD -0.30 (-1.71%)
Nov 10, 2026, 3:40 PM EST
17.11 Day range 18.34
11.37 52-week range 27.24
- YTD
- +9.52%
- 1 year
- +45.08%
News
benzinga.com Prenetics Global Collaborates With Authentic Brands Group To Build Care Bears By IM8 Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham,
prnewswire.com Care Bears And Prenetics' IM8 Announce Global Partnership IM8 family wellness brand to launch gummy multivitamins for kids and adults in 2027, marking Care Bears' 45th anniversary NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Care Bears, part of Authentic Brands…
globenewswire.com Prenetics' IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics Care Bears by IM8 to launch, with great-tasting, science-backed gummy multivitamins for kids and adults in 1H 2027 Enters a global gummy supplements market projected to nearly double to ~US$47.8…
benzinga.com Prenetics Global Appoints Brian J. Rosin CFO, Effective Dec. 31, Succeeding Stephen Lo Prenetics Global Limited (Nasdaq: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced that Brian J.…
globenewswire.com Prenetics' IM8 Names Brian J. Rosin as Successor Chief Financial Officer - Completes planned leadership transition as Prenetics revenue is almost entirely IM8 - Prenetics' finance leadership function now based in the United States - The Company will report third quarter…
benzinga.com Maxim Group Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $41 Maxim Group analyst Thomas Forte initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $41.- benzinga.com Lucid Capital Markets Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $54 Lucid Capital Markets analyst Alex Nowark initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $54.
benzinga.com Prenetics Global Q2 2026 Earnings Call: Complete Transcript Prenetics Global (NASDAQ:PRE) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought…
benzinga.com Craig-Hallum Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $40 Craig-Hallum analyst Eric Des Lauriers initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $40.- benzinga.com B. Riley Securities Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $37 B. Riley Securities analyst Jeff Van Sinderen initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $37.
benzinga.com Prenetics Global CEO Danny Yeung And CFO Brian Rosin Acquire Total Of $1M Worth Of Shares In Open Market Purchases Danny Yeung, Chief Executive OfficerPurchased 24,681 shares for approximately $502,000, at an average price of roughly $20.34 per share, across purchases on August 20 and August 24, 2026. This brings…- benzinga.com Prenetics Global Sees FY2026 Sales $220.000M-$230.000M vs $214.071M Est Prenetics Global (NASDAQ:PRE) sees FY2026 sales of $220.000 million-$230.000 million vs $214.071 million analyst estimate.
- benzinga.com Prenetics Global Q2 EPS $(0.53) Beats $(0.71) Estimate, Sales $46.488M Miss $48.920M Estimate Prenetics Global (NASDAQ:PRE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.71) by 25.35 percent. This is a 35.37 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
benzinga.com Benchmark Maintains Buy on Prenetics Global, Raises Price Target to $40 Benchmark analyst Bill Sutherland maintains Prenetics Global (NASDAQ:PRE) with a Buy and raises the price target from $30 to $40.- benzinga.com Prenetics Global Announces Closing Of $1B In Growth Financing From General Catalyst’s Customer Value Fund; Co. Raises FY26 IM8 Revenue Guidance To $210M-$220M, Up From $190M-$210M IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27…
- benzinga.com Benchmark Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $30 Benchmark analyst Bill Sutherland initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $30.
- benzinga.com Prenetics Global Affirms Q2 Sales Guidance of $46.000M-$48.000M vs $37.849M Est Prenetics Global (NASDAQ:PRE) affirms Q2 sales outlook from $46.000 million-$48.000 million to $46.000 million-$48.000 million vs $37.849 million estimate.
- benzinga.com Prenetics Global Q1 EPS $(1.61) Misses $(0.82) Estimate, Sales $35.954M Miss $37.849M Estimate Prenetics Global (NASDAQ:PRE) reported quarterly losses of $(1.61) per share which missed the analyst consensus estimate of $(0.82) by 96.34 percent. This is a 265.91 percent decrease over losses of…
benzinga.com Prenetics Global Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Lake Street Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $29 Lake Street analyst Ryan Meyers initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $29.
benzinga.com Prenetics Global Announces $40M Buyback Plan Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its…
benzinga.com Prenetics Global Introduces Daily Ultimate Essentials PRO Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced the launch of Daily…
benzinga.com Nasdaq Surges Over 1%; US Durable Goods Orders Fall In December - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Prenetics Global Sells Europa Sports Partners In All-Stock Transaction Valued At Up To $13M Company Continues Portfolio Optimization on the Heels of Successful $72 million ACT Genomics saleCompany Maintains Strong Balance Sheet with over $70 million in Cash and Cash Equivalents, 510 BTC and…
- benzinga.com Prenetics Global Enters Exchange Agreements For Class A, B Warrants, Reporting ~86.7% Participation Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced an update to its…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Prenetics Global Plans To Stop Purchase Of Bitcoin; Expects $180M To $200M In IM8 2026 Revenue Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, and parent of the IM8 premium health and longevity brand, today announced a strategic…
- benzinga.com Prenetics Launches Voluntary Warrant Exchange Program, Representing ~83.4% Of Outstanding Class A and B Warrants; Aims To Simplify Capital Structure, Reduce Potential Dilution By Up To 50%, Consolidate Legacy Warrants Into Single Class C Warrants Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has entered…
- benzinga.com Prenetics Global's Executives Acquire ~$1.4M Common Shares Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8 and a global health-tech and longevity company pioneering a dual-engine strategy across consumer…
- benzinga.com CORRECTION: Prenetics Global Affirms FY2025 Sales Guidance of $90.000M-$100.000M vs $99.200M Est Financial OutlookPrenetics reaffirms its full-year 2025 revenue guidance of $90 to $100 million (full-year 2025 revenue for IM8 expected to be $60 million).The Company provides Q4 2025 revenue…
- benzinga.com CORRECTION: Prenetics Global Raises FY2025 Sales Guidance from $85.000M-$100.000M to $90.000M-$100.000M vs $99.20M Est Financial OutlookPrenetics reaffirms its full-year 2025 revenue guidance of $90 to $100 million (full-year 2025 revenue for IM8 expected to be $60 million).The Company provides Q4 2025 revenue…
- benzinga.com Prenetics Global Q3 EPS $(0.41) Beats $(0.65) Estimate, Sales $23.555M Miss $25.200M Estimate Prenetics Global (NASDAQ:PRE) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.65) by 36.92 percent. This is a 47.44 percent increase over losses of…
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com Prenetics Global's Earnings: A Preview
- benzinga.com Prenetics Global Limited Announces Its IM8 Health And Longevity Brand Achieved A Record $108M In Annualized Recurring Revenue In October October Revenue Grew 32% MoM and on Track to hit $10 Million in Monthly Revenue by December 2025 ~ Prenetics Global Limited (NASDAQ:PRE) ("Prenetics"), a leading health sciences company and parent of…
- benzinga.com Prenetics Global Announces Acquisition Of 100 Bitcoin, At Average Price Of $109,594 Per Bitcoin Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity OfferingCompany now holds a total of 378 BTC (valued at ~$46 Million)CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) --…
- benzinga.com Cantor Fitzgerald Maintains Overweight on Prenetics Global, Raises Price Target to $32 Cantor Fitzgerald analyst Ross Osborn maintains Prenetics Global (NASDAQ:PRE) with a Overweight and raises the price target from $26 to $32.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Prenetics Prices $48M Best Efforts Public Offering Of 2,992,596 Shares And Warrants At A Combined Price Of $16.08 Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced the successful pricing of a best efforts public offering (the "Offering") of…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Reported Earlier: Prenetics Global Limited Launches Daily Ultimate Longevity From Its Rapidly Scaling IM8 Health Brand CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, today announced the launch of Daily Ultimate Longevity from its…
- benzinga.com Prenetics Global Teams Up with Aryna Sabalenka as IM8 Brand Ambassador and Shareholder Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David…
benzinga.com Prenetics Acquires $20 Million In Bitcoin To Boost Healthcare Bitcoin Treasury Strategy Prenetics Global Limited (PRE) completes $20 million BTC purchase, aims to become one of the largest healthcare corporate BTC holders globally.- benzinga.com Prenetics Global Secures $20M In BTC And Announces Pro-Forma Cash Strengthened To ~$66M With BTC And Short-Term Assets $117M - Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation- Following strategic divestiture, Prenetics…
- benzinga.com Scholar Rock Unloads Genomics Unit for $46M, Boosting Cash Reserves and Refocusing on Consumer Health Growth Prenetics Global Limited (NASDAQ:PRE) ("Prenetics"), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics…